Cargando…

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia

Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL). However, such resistance-conferring mutations are rare and do not explain most disease recurrence seen in the clinic. We have generated stable ATO-resistant promyelocyti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balasundaram, Nithya, Ganesan, Saravanan, Chendamarai, Ezhilarasi, Palani, Hamenth Kumar, Venkatraman, Arvind, Alex, Ansu Abu, David, Sachin, Kumar, Swathy Palani, Radhakrishnan, Nair Reeshma, Yasar, Mohammed, Krishna, Sanjeev, Korula, Anu, Kulkarni, Uday, Janet, Nancy Beryl, Balasubramanian, Poonkuzhali, Mathews, Vikram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791572/ https://www.ncbi.nlm.nih.gov/pubmed/34625794 http://dx.doi.org/10.1182/bloodadvances.2021005300

Ejemplares similares

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
por: Kulkarni, Uday, et al.
Publicado: (2020)

Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
por: Alex, Ansu Abu, et al.
Publicado: (2018)

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens
por: Fouzia, N. A., et al.
Publicado: (2020)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia
por: Ganesan, Saravanan, et al.
Publicado: (2019)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
por: Kulkarni, Uday, et al.
Publicado: (2023)

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia
por: Ganesan, S, et al.
Publicado: (2016)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias
por: Poplineau, Mathilde, et al.
Publicado: (2022)

Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
por: Song, Huan, et al.
Publicado: (2022)

Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
por: Short, Nicholas J., et al.
Publicado: (2023)

The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
por: Kumar, Rahul, et al.
Publicado: (2022)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma
por: Yamamoto, Tomofumi, et al.
Publicado: (2022)

The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
por: Lafage-Pochitaloff, Marina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vg8p0jkja3ec65emcgkos0eict